UniQure jumps 78% after FDA approval filing, as QURE $35 calls drew scrutiny
Social media post flags unusual buying in QURE $35 call options expiring July 17, 2026 shortly before the company said it was seeking FDA approval for Huntington’s disease gene therapy.
Fact Check
The originating @unusual_whales post matches the claim's framing exactly, flagging unusual $QURE $35 calls expiring 07/17/2026 ahead of the FDA news. Bloomberg confirms the FDA reversal allowing UniQure to file for US approval of its Huntington's disease gene therapy (June 17, 2026), and Benzinga and Yahoo Finance confirm the ~78% share surge. The factual scaffolding (FDA filing news, 78% jump, and the existence of the social-media post about the option activity) is well corroborated. The specific characterization of the options trading as suspicious/'drawing scrutiny' rests on the single @unusual_whales post rather than an independent regulatory finding, but the claim accurately describes that the post flagged this activity, so the overall statement is well supported.
Summary
UniQure shares rose 78% after the company announced it was seeking FDA approval for a Huntington’s disease gene therapy, while a social media post highlighted unusually large trading in QURE $35 call options before the news. The contracts cited were $35 calls expiring on July 17, 2026. Call options (contracts giving the right to buy shares at a set price) can surge in value when a stock rallies sharply, and the post said those traders made large gains. The post characterized the timing as unusual.
Terms & Concepts
- call options: Contracts giving the right to buy shares at a fixed price before expiration.
- FDA: U.S. Food and Drug Administration, the health regulator overseeing drug approvals.
- gene therapy: Treatment that aims to modify or deliver genetic material to address disease.